Neutralizing Antibodies to Interferon beta in patients treated with Re
Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Interferon beta-1a
Interferon alpha/beta receptor agonist
What it measured
Main measures
Primary endpoint:
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: 1. IFNβ naïve MS patients with RRMS. Exclusion: 1. Patients with a previous treatment history of IFNβ or IFN.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Primary objective: Prospective assessment of NAb development in interferon beta naïve patients initiated on Rebif New Formulation
Loading reviews and guidelines…
Related trials
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting
Phase 3 · Not yet recruiting
Still running
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Recruiting
Still running
- Discontinuation of first-line disease modifying treatment (DMT) in lon
Phase 4 · Stopped early
Stopped
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting
Still running
- Study to Investigate Pregnancy Outcomes in Female Participants Exposed
Completed
Paper found, not read
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017
Phase 3 · Running, not recruiting
Still running
History
Started
Jun 2009